Charles Explorer logo
🇬🇧

Bezpečnost empagliflozinu při chronickém onemocnění ledvin

Publication at First Faculty of Medicine |
2022

This text is not available in the current language. Showing version "cs".Abstract

Souhrn s komentářem. Citace: Tuttle KR, et al.

Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease: Pooled analysis of placebo-controlled clinical trials. Diabetes care. 2022 Jun 2; 45(6): 1445-1452.